GSK’s US$750 million cancer drug deal highlights China’s rise as biotech player
- Posted on September 16, 2026
- By South China Morning Post
- 0 Views
- 1 min read
In brief
Generating AI summary…
GSK’s US$750 million cancer drug deal highlights China’s rise as biotech player
The acquisition is the latest in a string of major licensing deals involving Chinese biotechnology firms.
